IP Library › Granted Patent US 10,487,133
Granted Patent B2
US 10,487,133 · App. 15/537,290 · Granted Nov 26, 2019

Codon optimization for titer and fidelity improvement

Inventor: Gang Yin (South San Francisco, CA)
Assignee: Sutro Biopharma, Inc.
C07K14/71C07K1/003C07K1/006C07K1/02C12N15/67C12P21/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,487,133
App. No.
15/537,290
Granted
Nov 26, 2019
Kind
B2
Abstract

The invention provides methods for producing a protein in a cell free protein synthesis system such that the protein does not contain an asparagine (Asn or N) residue at serine (Ser or S) positions. Also provided are compositions and nucleic acid templates for use in the methods described herein.

Claims (35)

1. A method for producing a full-length protein of interest in a cell free protein synthesis system said protein having multiple serine residues, the method comprising the steps of:

i) combining a nucleic acid template encoding the full-length protein with a cell free protein synthesis system;

wherein the template comprises codons encoding serine residues,

wherein the template has been modified such that no more than 10% of the codons encoding serine residues are AGC,

wherein at least one of the codons encoding serine residues in the template is AGT, TCA, or TCG; and

ii) incubating the template and the cell free protein synthesis system under conditions permitting the translation of the protein of interest.

2. The method of claim 1 , wherein the cell free protein synthesis system is derived from a bacterial cell.

3. The method of claim 2 , wherein the bacterial cell is an E. coli cell.

4. The method of claim 1 , wherein the cell free protein synthesis system has an active oxidative phosphorylation system.

5. The method of claim 1 , wherein the protein of interest is an antibody or a fragment thereof.

6. The method of claim 5 , wherein the antibody is IgG or IgE.

7. The method of claim 1 , wherein the protein of interest is produced at a concentration of greater than 6 mg/liter.

8. The method of claim 1 , wherein the protein of interest comprises amino acids wherein more than 15% of the amino acids are serine residues.

9. The method of claim 1 , wherein the codons encoding serine residues are selected from the group comprising of AGT, TCA, TCC, TCG and TCT.

10. The method of claim 1 , wherein the nucleic acid template has no AGC codons.

11. The method of claim 10 , wherein the nucleic acid template has no AGT codons.

12. A combination of a nucleic acid template and a cell free protein synthesis system for producing a protein of interest having a plurality of serine residues, the combination comprising:

a nucleic acid template encoding the protein of interest, wherein the nucleic acid template comprises codons encoding serine residues and wherein no more than 10% of the codons encoding the serine residues are AGC; and

a cell free protein synthesis system.

13. The combination of claim 12 , wherein the cell free protein synthesis system is derived from a bacterial cell.

14. The combination of claim 13 , wherein the bacterial cell is an E. coli cell.

15. The combination of claim 12 , wherein the cell free protein synthesis system has an active oxidative phosphorylation system.

16. The combination of claim 12 , wherein the protein of interest is an antibody or a fragment thereof.

17. The combination of claim 16 , wherein the antibody is IgG or IgE.

18. The combination of claim 12 , wherein the protein of interest is produced at a concentration of greater than 6 mg/liter.

19. The combination of claim 12 , wherein the protein of interest comprises amino acids wherein more than 15% of the amino acids are serine residues.

20. The combination of claim 12 , wherein the codons encoding the serine residues are selected from the group comprising of AGT, TCA, TCC, TCG and TCT.

21. The combination of claim 12 , wherein the nucleic acid template has no AGC codons.

22. The combination of claim 21 , wherein the nucleic acid template has no AGT codons.

23. A nucleic acid encoding a full-length protein of interest having a plurality of serine residues,

wherein the nucleic acid has been modified such that no more than 10% of the codons encoding the serine residues are AGC, and

wherein at least one of the codons encoding serine residues in the nucleic acid is AGT, TCA, or TCG.

24. The nucleic acid of claim 23 , wherein the protein of interest is an antibody.

25. The nucleic acid of claim 23 , wherein the protein of interest comprises amino acids wherein more than 15% of the amino acids are serine residues.

26. The nucleic acid of claim 23 , wherein the codons encoding serine residues are selected from the group consisting of AGT, TCA, TCC, TCG and TCT.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2017
From: YIN, GANG
To: SUTRO BIOPHARMA, INC.
Reel/Frame 044033/0177 →
Continuity (2)
Provisional Application 62094767 · Dec 19, 2014
Related Publication 20180051065A1 · Feb 22, 2018